Clinical Trials Market Size, Share & Trends Analysis Report and Segment
Forecast, 2026 | Grand View Research, Inc
“The global clinical trials market size was estimated at 44.2 billion in 2018 and
is anticipated to expand at a CAGR of 5.7% over the forecast period. ”
The global Clinical Trials Market size is expected to reach USD 68.9 billion by 2026, according to a new report
by Grand View Research, Inc. It is projected to expand at a CAGR of 5.7% during the forecast period . Key drivers
impacting the market growth are globalization of clinical trials, development of new treatments such as
personalized medicine, augmenting evolution in technology, and rising demand for CROs to conduct clinical
trials.
Globalization has led to increase in investment in new product development in emerging countries thereby,
positively impacting the market. The availability of the vast array of services from drug discovery to postmarketing surveillance has further simplified the life for mid-size and small-scale pharmaceutical and
biotechnological organizations by providing them the option to outsource what they think is beyond their core
expertise. For instance, Pfizer currently has three CROs working with it to enhance its product portfolio and
drive innovation. According to the partnership agreement with ICON in 2011, Pfizer would only preserve the
scientific ownership for the trials and studies conducted by ICON, hence allowing the company to focus and
further develop its capabilities in clinical trial designing.
Growing prevalence of disease and new disease cases is expected to give further boost to the clinical trial
market. Worldwide population has varied disease profile with emerging countries having the most diverse
disease profile. This is expected to boost the clinical trials of new or rare diseases which otherwise would not
Follow Us:
have found any sponsors. More number of patients having a specific disease would act as a stimulus for
biopharmaceutical companies to invest more in clinical trials for a disease segment.
To request a sample copy or view summary of this report, click the link below:
https://www.grandviewresearch.com/industry-analysis/global-clinical-trials-market
Further key findings from the report suggest:

The market is expected to be dominated by Phase III as of 2018, with Phase I anticipated to witness the
fastest growth

Increasing innovation and evolution of treatment is predicted to contribute towards growth of the
expanded access trials segment

Based on indication, the oncology segment is anticipated to witness the fastest growth. According to
various sources, more than USD 38.0 billion is currently being spent by the healthcare industry towards
preclinical and clinical development of oncology therapy products

North America led the overall clinical trials market in terms of revenue share in 2015 owing to the
presence of big outsourcing firms and increasing R&D in the region

Key players including Quintiles IMS, Paraxel International Corporation, Charles River Laboratories,
ICON plc, SGS SA among the others lead the global clinical trials market.
Grand View Research has segmented the global clinical trials market on the basis of phase, study design,
indication, and region:
Clinical Trials Phase Outlook (Revenue, USD Million, 2015 - 2026)

Phase I

Phase II

Phase III

Phase IV
Clinical Trials Study Design Outlook (Revenue, USD Million, 2015 - 2026)

Interventional

Observational

Expanded Access
Clinical Trials Indication Outlook (Revenue, USD Million, 2015 - 2026)
Follow Us:

Autoimmune/inflammation

Pain management

Oncology

CNS condition

Diabetes

Obesity

Cardiovascular

Others
Clinical Trials Regional Outlook (Revenue, USD Million, 2015 - 2026)




North America
o
U.S.
o
Canada
Europe
o
Germany
o
U.K.
o
France
o
Italy
o
Spain
Asia Pacific
o
China
o
Japan
o
India
o
Thailand
o
South Korea
Latin America
Follow Us:

o
Mexico
o
Brazil
o
Argentina
o
Colombia
MEA
Follow Us:
o
South Africa
o
Saudi Arabia
o
UAE
Table of Content of Clinical Trials Market
Chapter 1. Methodology and Scope
1.1. Market segmentation & scope
1.2. Information procurement
1.2.1. Purchased database
1.2.2. GVR’s internal database
1.2.3. Secondary sources & third party perspectives
1.2.4. Primary research
1.3. Information analysis
1.3.1. Data analysis models
1.4. Market formulation & data visualization
1.5. Data validation & publishing
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Product Pipeline Analysis
3.4. User perspective analysis
3.4.1. Consumer Behavior Analysis
3.4.2. Market Influencer Analysis
3.5. List of Key End-users, by region / by product / by country
3.6. Regulatory Framework
3.6.1. Reimbursement framework
3.6.2. Standards & Compliances
Follow Us:
3.7. Market Dynamics
3.7.1. Market Driver Analysis
3.7.1.1. Globalization of clinical trials
3.7.1.2. Adoption of new technology in clinical research
3.7.1.3. Growing disease variation and prevalence
3.7.1.4. Increasing research and development promoting outsourcing
3.7.2. Market Restraint Analysis
3.7.2.1. Regulations in new drug development
3.7.2.2. Pricing pressure
3.7.3. Industry Challenges
3.7.3.1. Rising cost of clinical trials
3.8. Clinical Trials: Market Analysis Tools
3.8.1. Industry Analysis - Porter’s
3.8.1.1. Supplier Power: (Moderate)
3.8.1.2. Buyer Power: (High)
3.8.1.3. Substitution Threat: (Low)
3.8.1.4. Threat from new entrant: (Low)
3.8.1.5. Competitive rivalry: (High)
3.8.2. PESTEL Analysis
3.8.2.1. Political Landscape
3.8.2.2. Environmental Landscape
3.8.2.3. Social Landscape
3.8.2.4. Technology Landscape
3.8.2.5. Legal Landscape
3.8.3. Major Deals & Strategic Alliances Analysis
3.8.3.1. Joint Ventures
3.8.3.2. Mergers & Acquisitions
3.8.3.3. Licensing & Partnership
3.8.3.4. Technology Collaborations
3.8.3.5. Strategic Divestments
3.8.4. Market Entry Strategies
Follow Us:
3.8.5. Case Studies
Chapter 4. Clinical Trials Market: Segment Analysis, By phase, 2015 - 2026 (USD Million)
4.1. Definitions & Scope
4.2. Phase market share analysis, 2018 & 2026
4.3. Segment Dashboard
4.4. Global Clinical Trials Market, by Phase, 2015 to 2026
4.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following
4.5.1. Phase I
4.5.2. Phase II
4.5.3. Phase III
4.5.4. Phase IV
Chapter 5. Clinical Trials Market: Segment Analysis, By Study Design, 2015 - 2026 (USD Million)
5.1. Definitions & Scope
5.2. Study design market share analysis, 2018 & 2026
5.3. Segment Dashboard
5.4. Global Clinical Trials Market, by study design, 2015 to 2026
5.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following
5.5.1. Interventional
5.5.2. Observational
5.5.3. Expanded access
Chapter 6. Clinical Trials Market: Segment Analysis, By Indication, 2015 - 2026 (USD Million)
6.1. Definitions & Scope
6.2. Indication market share analysis, 2018 & 2026
6.3. Segment Dashboard
6.4. Global Clinical Trials Market, by indication, 2015 to 2026
6.5. Market Size & Forecasts and Trend Analyses, 2015 to 2026 for the following
6.5.1. Autoimmune/inflammation
6.5.2. Pain management
6.5.3. Oncology
6.5.4. CNS condition
6.5.5. Diabetes
Follow Us:
6.5.6. Obesity
6.5.7. Cardiovascular
6.5.8. Others
Chapter 7. Clinical Trials Market: Regional Market Analysis, By Region, 2015 - 2026 (USD Million)
7.1. Definitions & Scope
7.2. Regional market share analysis, 2018 & 2026
7.3. Regional Market Dashboard
7.4. Regional Market Snapshot (Market Size, CAGR, Top Verticals, Key Players, Top Trends)
7.5. Regional Market Share and Leading Players, 2018
7.5.1. North America
7.5.2. Europe
7.5.3. Asia Pacific
7.5.4. Latin America
7.5.5. Middle East & Africa
7.6. SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
7.6.1. North America
7.6.2. Europe
7.6.3. Asia Pacific
7.6.4. Latin America
7.6.5. Middle East & Africa
7.7. Market Size, & Forecasts, Volume and Trend Analysis, 2018 to 2026:
7.8. North America
7.8.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
7.8.2. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.8.3. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.8.4. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.8.5. U.S.
7.8.5.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.8.5.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.8.5.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.8.6. Canada
Follow Us:
7.8.6.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.8.6.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.8.6.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.9. Europe
7.9.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
7.9.2. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.9.3. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.9.4. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.9.5. Germany
7.9.5.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.9.5.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.9.5.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.9.6. U.K.
7.9.6.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.9.6.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.9.6.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.9.7. France
7.9.7.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.9.7.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.9.7.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.9.8. Italy
7.9.8.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.9.8.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.9.8.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.9.9. Spain
7.9.9.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.9.9.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.9.9.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.10. Asia Pacific
7.10.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
7.10.2. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
Follow Us:
7.10.3. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.10.4. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.10.5. China
7.10.5.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.10.5.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.10.5.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.10.6. Japan
7.10.6.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.10.6.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.10.6.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.10.7. India
7.10.7.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.10.7.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.10.7.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.10.8. Thailand
7.10.8.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.10.8.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.10.8.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.10.9. South Korea
7.10.9.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.10.9.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.10.9.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.11. Latin America
7.11.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
7.11.2. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.11.3. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.11.4. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.11.5. Brazil
7.11.5.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.11.5.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.11.5.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
Follow Us:
7.11.6. Mexico
7.11.6.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.11.6.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.11.6.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.11.7. Argentina
7.11.7.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.11.7.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.11.7.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.11.8. Colombia
7.11.8.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.11.8.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.11.8.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.12. Middle East and Africa
7.12.1. Market estimates and forecast, by country, 2015 - 2026 (USD Million)
7.12.2. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.12.3. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.12.4. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.12.5. South Africa
7.12.5.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.12.5.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.12.5.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.12.6. Saudi Arabia
7.12.6.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.12.6.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.12.6.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
7.12.7. UAE
7.12.7.1. Market estimates and forecast, by phase, 2015 - 2026 (USD Million)
7.12.7.2. Market estimates and forecast, by study design, 2015 - 2026 (USD Million)
7.12.7.3. Market estimates and forecast, by indication, 2015 - 2026 (USD Million)
Chapter 8. Clinical Trials Market - Competitive Analysis
8.1. Recent developments & impact analysis, by key market participants
Follow Us:
8.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company market share analysis, 2018
8.4. Public Companies
8.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key
serviceable industries, key alliances)
8.4.2. Company Market Share/Ranking, by region
8.4.3. Competitive Dashboard Analysis
8.4.3.1. Market Differentiators
8.4.3.2. Synergy Analysis: Major Deals & Strategic Alliances
8.5. Private Companies
8.5.1. List of key emerging companies’ /technology disruptors/innovators
8.5.2. Funding Outlook (Optional)
8.5.3. Regional network map
8.5.4. Company market position analysis (geographic presence, product portfolio, key alliance, industry
experience)
8.6. Supplier Ranking
8.7. Key companies profiled
8.7.1. IQVIA
8.7.1.1. Company Overview
8.7.1.2. Financial Performance
8.7.1.3. Product Benchmarking
8.7.1.4. Strategic Initiatives
8.7.2. PAREXEL International Corporation.
8.7.2.1. Company Overview
8.7.2.2. Financial Performance
8.7.2.3. Product Benchmarking
8.7.2.4. Strategic Initiatives
8.7.3. Pharmaceutical Product Development, LLC
Follow Us:
8.7.3.1. Company Overview
8.7.3.2. Financial Performance
8.7.3.3. Product Benchmarking
8.7.3.4. Strategic Initiatives
8.7.4. Charles River Laboratory.
8.7.4.1. Company Overview
8.7.4.2. Financial Performance
8.7.4.3. Product Benchmarking
8.7.4.4. Strategic Initiatives
8.7.5. ICON Plc.
8.7.5.1. Company Overview
8.7.5.2. Financial Performance
8.7.5.3. Product Benchmarking
8.7.5.4. Strategic Initiatives
8.7.6. Wuxi AppTec Inc.
8.7.6.1. Company Overview
8.7.6.2. Financial Performance
8.7.6.3. Product Benchmarking
8.7.6.4. Strategic Initiatives
8.7.7. PRA Health Sciences.
8.7.7.1. Company Overview
8.7.7.2. Financial Performance
8.7.7.3. Product Benchmarking
8.7.7.4. Strategic Initiatives
8.7.8. SGS SA.
8.7.8.1. Company Overview
8.7.8.2. Financial Performance
8.7.8.3. Product Benchmarking
8.7.8.4. Strategic Initiatives
8.7.9. Syneos Health.
8.7.9.1. Company Overview
Follow Us:
8.7.9.2. Financial Performance
8.7.9.3. Product Benchmarking
8.7.9.4. Strategic Initiatives
8.7.10. Chiltern International Ltd.
8.7.10.1. Company Overview
8.7.10.2. Financial Performance
8.7.10.3. Product Benchmarking
8.7.10.4. Strategic Initiatives
Chapter 9. KOL Commentary
Chapter 10. Recommendation
Follow Us:
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed business decisions, the company offers
market intelligence studies ensuring relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: [email protected]
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Follow Us:

The global clinical trials market size is expected to reach USD 68.9 billion by 2026, according to a new report by Grand View Research, Inc.